Semler Scientific is lowering its IPO price, now seeking $10 million instead of the previous $15 million it desired.
Portland, Ore.-based Semler specializes in medical risk-assessment. The company’s flagship product is the FloChec, which tracks blood flow in lower and upper extremities. The device is cleared by the FDA, according to the company’s website.
SMLR plans on adjusting its price range to $7.50-$9.50, down from $12-$14 apiece for its 1.2 million shares. The company is expected to go public this week, according to a press release.